Publications by authors named "C R Flowers"
Background: Adoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Progression of disease within 24 months of initial immunochemotherapy (POD24) in follicular lymphoma (FL) is linked to worse patient outcomes, and there is currently no standard treatment for these patients.
- A study of 256 FL patients with POD24 revealed diverse treatment approaches, with bendamustine-rituximab patients mostly receiving R-CHOP therapy and R-CHOP patients opting for aggressive salvage therapy.
- The overall response rate to treatments after POD24 was 66%, with a complete response rate of 40%, while factors like age over 70 and high-risk FLIPI scores worsened overall survival outcomes (73% at 5 years).
Article Synopsis
- * Between 2004 and 2022, MRI awarded scholarships to 405 individuals, and those who received funding had significantly lower dropout rates compared to national averages: 0% for graduate students and 2.2% for medical students.
- * The initiative also showed that awardees were more likely to stay in the hematology-oncology field than national minority averages, with 14.4% of medical students and 88.5% of early-career
Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT).
Methods And Materials: We retrospectively reviewed 35 patients treated with Ann Arbor stage I/II ENKTCL between 1994 and 2015 at a large academic cancer center in the United States.
Results: With 11.
Antibiotic-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T (CAR-T) cell therapies. In this study, we observed that prior exposure to broad-spectrum ABX with extended anaerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B-cell lymphoma patients (n=422), compared to other ABX classes. In a discovery subset of these patients (n=67), we found that the use of these ABX was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n=58).
View Article and Find Full Text PDF